Chemotherapy beyond second-line in advanced gastric cancer

doi:10.3748/wjg.v21.i29.8811

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 29

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11501)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

624

WORD

335

HTML

4531

Tables (1-1)

572

Sum=6062

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

585

Download

1636

Sum=2221

Publishing Process of This Article

Item

Count

Browse

1161

Download

2057

Sum=3218

Aug 7, 2015 (publication date) through Oct 31, 2025

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Gastroenterol. Aug 7, 2015; 21(29): 8811-8816
Published online Aug 7, 2015. doi: 10.3748/wjg.v21.i29.8811

Table 1 Randomized phase III trials in the second-line treatment of gastric cancer

Trials	Treatment	No. of patients	OS (mo)	HR for OS(95%CI)	Remarks
AIO[8]	Irinotecan	21	4.0	0.48 (0.25-0.92)	Closed early due to poor accrual
AIO[8]	BSC	19	2.4	P = 0.012	Closed early due to poor accrual
Korean[9]	Docetaxel or irinotecan	133	5.3	0.657 (0.485-0.891)	No OS difference between docetaxel (5.5 mo) and irinotecan (6.5 mo)
Korean[9]	BSC	69	3.8	P = 0.007
COUGAR-02[10]	Docetaxel	84	5.2	0.67 (0.49-0.92)	Global QOL similar between arms (P = 0.53)
COUGAR-02[10]	BSC	84	3.6	P = 0.01	Global QOL similar between arms (P = 0.53)
REGARD[11]	Ramucirumab	238	5.2	0.776 (0.603-0.998)
REGARD[11]	Placebo	117	3.8	P = 0.047
RAINBOW[12]	Ramucirumab + paclitaxel	330	9.6	0.807 (0.678-0.962)
RAINBOW[12]	Placebo + paclitaxel	335	7.4	P = 0.017
WJOG 4007[15]	Paclitaxel	108	9.5	1.14 (0.88-1.49)
WJOG 4007[15]	Irinotecan	111	8.4	P = 0.24

BSC: Best supportive care; QOL: Quality of life.

Full Size Table

Citation: Kim SM, Park SH. Chemotherapy beyond second-line in advanced gastric cancer. World J Gastroenterol 2015; 21(29): 8811-8816
URL: https://www.wjgnet.com/1007-9327/full/v21/i29/8811.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i29.8811